Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Viage Says Zhongze-Partnered Gut-Based Therapy Effective for Cognitive Decline

publication date: Jul 26, 2023

San Francisco’s Viage Therapeutics, a neuroscience company, reported positive data from a Phase I trial of DGX-001, a first-in class oral drug targeting the AVPR1A receptor in the gut, showing changes in subjects’ brain activity as measured by qEEG. Shanghai Zhongze Pharma owns China rights to DGX-001 and participated in Viage’s $10 million seed financing. Viage develops drugs that stimulate the nervous system via the vagus nerve, which connects the gut to the brain. Viage plans a Phase II trial of DGX-001 in Alzheimer's Disease and Parkinson's Disease patients with mild cognitive impairment. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital